Related Experiment Videos
The gamma-hydroxybutyrate withdrawal syndrome
Asim F Tarabar1, Lewis S Nelson
1New York City Poison Control Center, New York, New York, USA. asim.tarabar@yale.edu
Toxicological Reviews
|August 10, 2004
Summary
gamma-Hydroxybutyrate (GHB) is a sedative-hypnotic drug with medical uses, but also recreational abuse potential. Chronic GHB use can lead to severe withdrawal symptoms resembling alcohol or benzodiazepine withdrawal.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- gamma-Hydroxybutyrate (GHB) is an endogenous inhibitory neurotransmitter with sedative-hypnotic properties.
- GHB has therapeutic applications in anesthesia, narcolepsy, and substance detoxification.
- Recreational GHB use emerged due to its euphoric effects, leading to widespread abuse and the use of precursor substances.
Purpose of the Study:
- To review the medical uses, recreational abuse, and withdrawal characteristics of gamma-Hydroxybutyrate (GHB).
- To describe the clinical presentation and management of GHB withdrawal syndrome.
Main Methods:
- Literature review of GHB's pharmacological properties, clinical uses, and patterns of abuse.
- Analysis of clinical features of GHB withdrawal compared to other sedative-hypnotic withdrawal syndromes.
Main Results:
- GHB and its precursors can induce tolerance and dependence.
- Withdrawal from chronic heavy GHB use can be severe, clinically similar to alcohol and benzodiazepine withdrawal.
- GHB withdrawal is characterized by mild autonomic instability and prolonged psychotic symptoms.
Conclusions:
- GHB withdrawal requires management with cross-tolerant sedative-hypnotics like benzodiazepines.
- Understanding GHB's effects and withdrawal is crucial for clinical practice and public health.
- The study highlights the risks associated with GHB abuse and the need for effective treatment strategies.